nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—Ergolines—Bromocriptine—type 2 diabetes mellitus	0.447	1	CiPCiCtD
Cabergoline—Parkinson's disease—Bromocriptine—type 2 diabetes mellitus	0.172	1	CpDpCtD
Cabergoline—ADRA2A—type 2 diabetes mellitus	0.0474	0.42	CbGaD
Cabergoline—HTR2C—type 2 diabetes mellitus	0.0437	0.387	CbGaD
Cabergoline—CYP3A4—type 2 diabetes mellitus	0.0218	0.193	CbGaD
Cabergoline—DRD5—Bromocriptine—type 2 diabetes mellitus	0.0156	0.0934	CbGbCtD
Cabergoline—HTR7—Bromocriptine—type 2 diabetes mellitus	0.0114	0.0685	CbGbCtD
Cabergoline—DRD4—Bromocriptine—type 2 diabetes mellitus	0.0111	0.0666	CbGbCtD
Cabergoline—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.00915	0.0548	CbGbCtD
Cabergoline—HTR2B—Bromocriptine—type 2 diabetes mellitus	0.00895	0.0536	CbGbCtD
Cabergoline—ADRA1D—Bromocriptine—type 2 diabetes mellitus	0.00877	0.0525	CbGbCtD
Cabergoline—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.00877	0.0525	CbGbCtD
Cabergoline—DRD3—Bromocriptine—type 2 diabetes mellitus	0.00827	0.0495	CbGbCtD
Cabergoline—DRD1—Bromocriptine—type 2 diabetes mellitus	0.00796	0.0477	CbGbCtD
Cabergoline—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.00796	0.0477	CbGbCtD
Cabergoline—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.00755	0.0452	CbGbCtD
Cabergoline—ADRB1—Bromocriptine—type 2 diabetes mellitus	0.00686	0.0411	CbGbCtD
Cabergoline—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.00638	0.0382	CbGbCtD
Cabergoline—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.00583	0.0349	CbGbCtD
Cabergoline—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.00549	0.0329	CbGbCtD
Cabergoline—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.00525	0.0315	CbGbCtD
Cabergoline—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.00525	0.0315	CbGbCtD
Cabergoline—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.00504	0.0302	CbGbCtD
Cabergoline—DRD2—Bromocriptine—type 2 diabetes mellitus	0.00484	0.029	CbGbCtD
Cabergoline—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00251	0.015	CbGbCtD
Cabergoline—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00224	0.0134	CbGbCtD
Cabergoline—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00205	0.0123	CbGbCtD
Cabergoline—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00179	0.0107	CbGbCtD
Cabergoline—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00162	0.00969	CbGbCtD
Cabergoline—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00123	0.00734	CbGbCtD
Cabergoline—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00117	0.00704	CbGbCtD
Cabergoline—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00117	0.00704	CbGbCtD
Cabergoline—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00111	0.00665	CbGbCtD
Cabergoline—CYP3A4—Glyburide—type 2 diabetes mellitus	0.000828	0.00496	CbGbCtD
Cabergoline—HTR7—sympathetic nervous system—type 2 diabetes mellitus	0.000801	0.0779	CbGeAlD
Cabergoline—HTR2A—arteriole—type 2 diabetes mellitus	0.000784	0.0762	CbGeAlD
Cabergoline—CYP3A4—Losartan—type 2 diabetes mellitus	0.000757	0.00453	CbGbCtD
Cabergoline—HTR7—autonomic nervous system—type 2 diabetes mellitus	0.000539	0.0523	CbGeAlD
Cabergoline—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.0005	0.0486	CbGeAlD
Cabergoline—DRD1—nerve—type 2 diabetes mellitus	0.000485	0.0471	CbGeAlD
Cabergoline—HTR1B—artery—type 2 diabetes mellitus	0.000396	0.0385	CbGeAlD
Cabergoline—HTR7—peripheral nervous system—type 2 diabetes mellitus	0.000389	0.0378	CbGeAlD
Cabergoline—HTR1D—artery—type 2 diabetes mellitus	0.000383	0.0373	CbGeAlD
Cabergoline—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000336	0.0326	CbGeAlD
Cabergoline—HTR2A—hindlimb—type 2 diabetes mellitus	0.000311	0.0302	CbGeAlD
Cabergoline—HTR7—artery—type 2 diabetes mellitus	0.000305	0.0297	CbGeAlD
Cabergoline—HTR7—nerve—type 2 diabetes mellitus	0.000303	0.0294	CbGeAlD
Cabergoline—DRD2—nerve—type 2 diabetes mellitus	0.000286	0.0278	CbGeAlD
Cabergoline—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000285	0.0277	CbGeAlD
Cabergoline—HTR7—endothelium—type 2 diabetes mellitus	0.000258	0.0251	CbGeAlD
Cabergoline—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000242	0.0236	CbGeAlD
Cabergoline—Pergolide—ADRA2A—type 2 diabetes mellitus	0.000197	0.225	CrCbGaD
Cabergoline—HTR2A—artery—type 2 diabetes mellitus	0.00019	0.0185	CbGeAlD
Cabergoline—HTR2A—nerve—type 2 diabetes mellitus	0.000189	0.0184	CbGeAlD
Cabergoline—Pergolide—HTR2C—type 2 diabetes mellitus	0.000181	0.207	CrCbGaD
Cabergoline—ADRA1B—kidney—type 2 diabetes mellitus	0.000178	0.0173	CbGeAlD
Cabergoline—Lisuride—ADRA2A—type 2 diabetes mellitus	0.000171	0.195	CrCbGaD
Cabergoline—HTR2A—endothelium—type 2 diabetes mellitus	0.000161	0.0156	CbGeAlD
Cabergoline—Lisuride—HTR2C—type 2 diabetes mellitus	0.000157	0.18	CrCbGaD
Cabergoline—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000138	0.0134	CbGeAlD
Cabergoline—HTR1D—cardiovascular system—type 2 diabetes mellitus	0.000133	0.0129	CbGeAlD
Cabergoline—HTR1D—kidney—type 2 diabetes mellitus	0.00013	0.0127	CbGeAlD
Cabergoline—ADRB1—cardiovascular system—type 2 diabetes mellitus	0.000129	0.0126	CbGeAlD
Cabergoline—HTR2B—cardiovascular system—type 2 diabetes mellitus	0.000124	0.012	CbGeAlD
Cabergoline—DRD2—retina—type 2 diabetes mellitus	0.000119	0.0115	CbGeAlD
Cabergoline—HTR2B—cortex of kidney—type 2 diabetes mellitus	0.000118	0.0115	CbGeAlD
Cabergoline—ADRB1—adipose tissue—type 2 diabetes mellitus	0.000114	0.0111	CbGeAlD
Cabergoline—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000111	0.0108	CbGeAlD
Cabergoline—HTR2B—adipose tissue—type 2 diabetes mellitus	0.000109	0.0106	CbGeAlD
Cabergoline—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000109	0.0106	CbGeAlD
Cabergoline—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000108	0.0105	CbGeAlD
Cabergoline—HTR7—cardiovascular system—type 2 diabetes mellitus	0.000106	0.0103	CbGeAlD
Cabergoline—HTR7—kidney—type 2 diabetes mellitus	0.000104	0.0101	CbGeAlD
Cabergoline—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000102	0.00995	CbGeAlD
Cabergoline—ADRA2C—kidney—type 2 diabetes mellitus	9.54e-05	0.00928	CbGeAlD
Cabergoline—ADRA2C—pancreas—type 2 diabetes mellitus	9.48e-05	0.00921	CbGeAlD
Cabergoline—ADRA2C—cortex of kidney—type 2 diabetes mellitus	9.29e-05	0.00903	CbGeAlD
Cabergoline—Pergolide—CYP3A4—type 2 diabetes mellitus	9.06e-05	0.103	CrCbGaD
Cabergoline—ADRA1A—adipose tissue—type 2 diabetes mellitus	9.03e-05	0.00877	CbGeAlD
Cabergoline—ADRA2C—adipose tissue—type 2 diabetes mellitus	8.6e-05	0.00836	CbGeAlD
Cabergoline—Lisuride—CYP3A4—type 2 diabetes mellitus	7.86e-05	0.0898	CrCbGaD
Cabergoline—HTR2A—retina—type 2 diabetes mellitus	7.82e-05	0.0076	CbGeAlD
Cabergoline—ADRA2A—pancreas—type 2 diabetes mellitus	7.56e-05	0.00735	CbGeAlD
Cabergoline—ADRA2A—cortex of kidney—type 2 diabetes mellitus	7.42e-05	0.00721	CbGeAlD
Cabergoline—ADRA2A—adipose tissue—type 2 diabetes mellitus	6.86e-05	0.00667	CbGeAlD
Cabergoline—HTR2A—cardiovascular system—type 2 diabetes mellitus	6.62e-05	0.00643	CbGeAlD
Cabergoline—HTR7—liver—type 2 diabetes mellitus	6.56e-05	0.00638	CbGeAlD
Cabergoline—HTR2A—kidney—type 2 diabetes mellitus	6.47e-05	0.00629	CbGeAlD
Cabergoline—ADRA1A—liver—type 2 diabetes mellitus	6.33e-05	0.00615	CbGeAlD
Cabergoline—ADRA2C—liver—type 2 diabetes mellitus	6.03e-05	0.00586	CbGeAlD
Cabergoline—CYP3A4—kidney—type 2 diabetes mellitus	5.99e-05	0.00583	CbGeAlD
Cabergoline—HTR2A—liver—type 2 diabetes mellitus	4.09e-05	0.00398	CbGeAlD
Cabergoline—CYP3A4—liver—type 2 diabetes mellitus	3.79e-05	0.00368	CbGeAlD
Cabergoline—Loss of consciousness—Metformin—type 2 diabetes mellitus	3.12e-05	0.000577	CcSEcCtD
Cabergoline—Paraesthesia—Gliclazide—type 2 diabetes mellitus	3.11e-05	0.000575	CcSEcCtD
Cabergoline—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	3.11e-05	0.000575	CcSEcCtD
Cabergoline—Flatulence—Losartan—type 2 diabetes mellitus	3.11e-05	0.000575	CcSEcCtD
Cabergoline—Tension—Losartan—type 2 diabetes mellitus	3.09e-05	0.000572	CcSEcCtD
Cabergoline—Dizziness—Glimepiride—type 2 diabetes mellitus	3.09e-05	0.000572	CcSEcCtD
Cabergoline—Dyspnoea—Gliclazide—type 2 diabetes mellitus	3.09e-05	0.000571	CcSEcCtD
Cabergoline—Dizziness—Sitagliptin—type 2 diabetes mellitus	3.08e-05	0.00057	CcSEcCtD
Cabergoline—Somnolence—Gliclazide—type 2 diabetes mellitus	3.08e-05	0.000569	CcSEcCtD
Cabergoline—Hypertension—Metformin—type 2 diabetes mellitus	3.06e-05	0.000567	CcSEcCtD
Cabergoline—Nervousness—Losartan—type 2 diabetes mellitus	3.06e-05	0.000566	CcSEcCtD
Cabergoline—Oedema peripheral—Ramipril—type 2 diabetes mellitus	3.06e-05	0.000566	CcSEcCtD
Cabergoline—Back pain—Losartan—type 2 diabetes mellitus	3.05e-05	0.000564	CcSEcCtD
Cabergoline—Abdominal pain—Glyburide—type 2 diabetes mellitus	3.05e-05	0.000564	CcSEcCtD
Cabergoline—Dyspepsia—Gliclazide—type 2 diabetes mellitus	3.05e-05	0.000564	CcSEcCtD
Cabergoline—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	3.04e-05	0.000562	CcSEcCtD
Cabergoline—Anorexia—Valsartan—type 2 diabetes mellitus	3.03e-05	0.000561	CcSEcCtD
Cabergoline—Muscle spasms—Losartan—type 2 diabetes mellitus	3.03e-05	0.000561	CcSEcCtD
Cabergoline—Asthenia—Bromocriptine—type 2 diabetes mellitus	3.03e-05	0.00056	CcSEcCtD
Cabergoline—Malaise—Irbesartan—type 2 diabetes mellitus	3.02e-05	0.000559	CcSEcCtD
Cabergoline—Vertigo—Irbesartan—type 2 diabetes mellitus	3.01e-05	0.000557	CcSEcCtD
Cabergoline—Headache—Pioglitazone—type 2 diabetes mellitus	3.01e-05	0.000556	CcSEcCtD
Cabergoline—Syncope—Irbesartan—type 2 diabetes mellitus	3e-05	0.000556	CcSEcCtD
Cabergoline—Visual impairment—Ramipril—type 2 diabetes mellitus	2.99e-05	0.000554	CcSEcCtD
Cabergoline—Discomfort—Metformin—type 2 diabetes mellitus	2.98e-05	0.000552	CcSEcCtD
Cabergoline—Fatigue—Gliclazide—type 2 diabetes mellitus	2.98e-05	0.000552	CcSEcCtD
Cabergoline—Nausea—Glipizide—type 2 diabetes mellitus	2.98e-05	0.00055	CcSEcCtD
Cabergoline—Vomiting—Glimepiride—type 2 diabetes mellitus	2.97e-05	0.00055	CcSEcCtD
Cabergoline—Hypotension—Valsartan—type 2 diabetes mellitus	2.97e-05	0.00055	CcSEcCtD
Cabergoline—Vomiting—Sitagliptin—type 2 diabetes mellitus	2.96e-05	0.000548	CcSEcCtD
Cabergoline—Pain—Gliclazide—type 2 diabetes mellitus	2.96e-05	0.000548	CcSEcCtD
Cabergoline—Constipation—Gliclazide—type 2 diabetes mellitus	2.96e-05	0.000548	CcSEcCtD
Cabergoline—Rash—Glimepiride—type 2 diabetes mellitus	2.95e-05	0.000545	CcSEcCtD
Cabergoline—Dermatitis—Glimepiride—type 2 diabetes mellitus	2.94e-05	0.000545	CcSEcCtD
Cabergoline—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	2.94e-05	0.000545	CcSEcCtD
Cabergoline—Rash—Sitagliptin—type 2 diabetes mellitus	2.94e-05	0.000544	CcSEcCtD
Cabergoline—Dermatitis—Sitagliptin—type 2 diabetes mellitus	2.94e-05	0.000543	CcSEcCtD
Cabergoline—Headache—Glimepiride—type 2 diabetes mellitus	2.93e-05	0.000542	CcSEcCtD
Cabergoline—Ill-defined disorder—Losartan—type 2 diabetes mellitus	2.92e-05	0.000541	CcSEcCtD
Cabergoline—Headache—Sitagliptin—type 2 diabetes mellitus	2.92e-05	0.00054	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	2.9e-05	0.000536	CcSEcCtD
Cabergoline—Oedema—Metformin—type 2 diabetes mellitus	2.9e-05	0.000536	CcSEcCtD
Cabergoline—Hypertension—Irbesartan—type 2 diabetes mellitus	2.89e-05	0.000535	CcSEcCtD
Cabergoline—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	2.89e-05	0.000534	CcSEcCtD
Cabergoline—Insomnia—Valsartan—type 2 diabetes mellitus	2.88e-05	0.000532	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	2.86e-05	0.00053	CcSEcCtD
Cabergoline—Paraesthesia—Valsartan—type 2 diabetes mellitus	2.86e-05	0.000528	CcSEcCtD
Cabergoline—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	2.85e-05	0.000528	CcSEcCtD
Cabergoline—Arthralgia—Irbesartan—type 2 diabetes mellitus	2.85e-05	0.000528	CcSEcCtD
Cabergoline—Shock—Metformin—type 2 diabetes mellitus	2.85e-05	0.000527	CcSEcCtD
Cabergoline—Insomnia—Orlistat—type 2 diabetes mellitus	2.84e-05	0.000526	CcSEcCtD
Cabergoline—Malaise—Losartan—type 2 diabetes mellitus	2.84e-05	0.000526	CcSEcCtD
Cabergoline—Anxiety—Irbesartan—type 2 diabetes mellitus	2.84e-05	0.000526	CcSEcCtD
Cabergoline—Hypersensitivity—Glyburide—type 2 diabetes mellitus	2.84e-05	0.000525	CcSEcCtD
Cabergoline—Dyspnoea—Valsartan—type 2 diabetes mellitus	2.84e-05	0.000525	CcSEcCtD
Cabergoline—Vertigo—Losartan—type 2 diabetes mellitus	2.83e-05	0.000524	CcSEcCtD
Cabergoline—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	2.83e-05	0.000524	CcSEcCtD
Cabergoline—Somnolence—Valsartan—type 2 diabetes mellitus	2.83e-05	0.000523	CcSEcCtD
Cabergoline—Syncope—Losartan—type 2 diabetes mellitus	2.83e-05	0.000523	CcSEcCtD
Cabergoline—Paraesthesia—Orlistat—type 2 diabetes mellitus	2.82e-05	0.000522	CcSEcCtD
Cabergoline—Discomfort—Irbesartan—type 2 diabetes mellitus	2.82e-05	0.000521	CcSEcCtD
Cabergoline—Hyperhidrosis—Metformin—type 2 diabetes mellitus	2.8e-05	0.000518	CcSEcCtD
Cabergoline—Dyspepsia—Valsartan—type 2 diabetes mellitus	2.8e-05	0.000518	CcSEcCtD
Cabergoline—Dizziness—Bromocriptine—type 2 diabetes mellitus	2.79e-05	0.000516	CcSEcCtD
Cabergoline—Dry mouth—Irbesartan—type 2 diabetes mellitus	2.79e-05	0.000516	CcSEcCtD
Cabergoline—Palpitations—Losartan—type 2 diabetes mellitus	2.78e-05	0.000515	CcSEcCtD
Cabergoline—Nausea—Glimepiride—type 2 diabetes mellitus	2.78e-05	0.000514	CcSEcCtD
Cabergoline—Arrhythmia—Ramipril—type 2 diabetes mellitus	2.77e-05	0.000513	CcSEcCtD
Cabergoline—Loss of consciousness—Losartan—type 2 diabetes mellitus	2.77e-05	0.000513	CcSEcCtD
Cabergoline—Nausea—Sitagliptin—type 2 diabetes mellitus	2.77e-05	0.000512	CcSEcCtD
Cabergoline—Dyspepsia—Orlistat—type 2 diabetes mellitus	2.77e-05	0.000512	CcSEcCtD
Cabergoline—Asthenia—Glyburide—type 2 diabetes mellitus	2.77e-05	0.000512	CcSEcCtD
Cabergoline—Decreased appetite—Valsartan—type 2 diabetes mellitus	2.76e-05	0.000512	CcSEcCtD
Cabergoline—Anorexia—Metformin—type 2 diabetes mellitus	2.76e-05	0.000511	CcSEcCtD
Cabergoline—Alopecia—Ramipril—type 2 diabetes mellitus	2.74e-05	0.000508	CcSEcCtD
Cabergoline—Fatigue—Valsartan—type 2 diabetes mellitus	2.74e-05	0.000507	CcSEcCtD
Cabergoline—Abdominal pain—Gliclazide—type 2 diabetes mellitus	2.74e-05	0.000506	CcSEcCtD
Cabergoline—Oedema—Irbesartan—type 2 diabetes mellitus	2.73e-05	0.000506	CcSEcCtD
Cabergoline—Decreased appetite—Orlistat—type 2 diabetes mellitus	2.73e-05	0.000505	CcSEcCtD
Cabergoline—Pruritus—Glyburide—type 2 diabetes mellitus	2.73e-05	0.000505	CcSEcCtD
Cabergoline—Constipation—Valsartan—type 2 diabetes mellitus	2.72e-05	0.000503	CcSEcCtD
Cabergoline—Fatigue—Orlistat—type 2 diabetes mellitus	2.71e-05	0.000501	CcSEcCtD
Cabergoline—Hypotension—Metformin—type 2 diabetes mellitus	2.71e-05	0.000501	CcSEcCtD
Cabergoline—Shock—Irbesartan—type 2 diabetes mellitus	2.69e-05	0.000498	CcSEcCtD
Cabergoline—Pain—Orlistat—type 2 diabetes mellitus	2.69e-05	0.000497	CcSEcCtD
Cabergoline—Arthralgia—Losartan—type 2 diabetes mellitus	2.68e-05	0.000496	CcSEcCtD
Cabergoline—Vomiting—Bromocriptine—type 2 diabetes mellitus	2.68e-05	0.000496	CcSEcCtD
Cabergoline—Anxiety—Losartan—type 2 diabetes mellitus	2.67e-05	0.000495	CcSEcCtD
Cabergoline—Rash—Bromocriptine—type 2 diabetes mellitus	2.66e-05	0.000492	CcSEcCtD
Cabergoline—Dermatitis—Bromocriptine—type 2 diabetes mellitus	2.66e-05	0.000491	CcSEcCtD
Cabergoline—Tension—Ramipril—type 2 diabetes mellitus	2.65e-05	0.000491	CcSEcCtD
Cabergoline—Discomfort—Losartan—type 2 diabetes mellitus	2.65e-05	0.00049	CcSEcCtD
Cabergoline—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	2.64e-05	0.000489	CcSEcCtD
Cabergoline—Headache—Bromocriptine—type 2 diabetes mellitus	2.64e-05	0.000489	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	2.64e-05	0.000488	CcSEcCtD
Cabergoline—Diarrhoea—Glyburide—type 2 diabetes mellitus	2.64e-05	0.000488	CcSEcCtD
Cabergoline—Nervousness—Ramipril—type 2 diabetes mellitus	2.62e-05	0.000486	CcSEcCtD
Cabergoline—Dry mouth—Losartan—type 2 diabetes mellitus	2.62e-05	0.000486	CcSEcCtD
Cabergoline—Anorexia—Irbesartan—type 2 diabetes mellitus	2.6e-05	0.000482	CcSEcCtD
Cabergoline—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	2.6e-05	0.000481	CcSEcCtD
Cabergoline—Paraesthesia—Metformin—type 2 diabetes mellitus	2.6e-05	0.000481	CcSEcCtD
Cabergoline—Muscle spasms—Ramipril—type 2 diabetes mellitus	2.6e-05	0.000481	CcSEcCtD
Cabergoline—Confusional state—Losartan—type 2 diabetes mellitus	2.59e-05	0.00048	CcSEcCtD
Cabergoline—Feeling abnormal—Orlistat—type 2 diabetes mellitus	2.59e-05	0.000479	CcSEcCtD
Cabergoline—Dyspnoea—Metformin—type 2 diabetes mellitus	2.58e-05	0.000478	CcSEcCtD
Cabergoline—Somnolence—Metformin—type 2 diabetes mellitus	2.57e-05	0.000476	CcSEcCtD
Cabergoline—Oedema—Losartan—type 2 diabetes mellitus	2.57e-05	0.000476	CcSEcCtD
Cabergoline—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	2.57e-05	0.000475	CcSEcCtD
Cabergoline—Hypotension—Irbesartan—type 2 diabetes mellitus	2.55e-05	0.000473	CcSEcCtD
Cabergoline—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	2.55e-05	0.000472	CcSEcCtD
Cabergoline—Dyspepsia—Metformin—type 2 diabetes mellitus	2.55e-05	0.000472	CcSEcCtD
Cabergoline—Shock—Losartan—type 2 diabetes mellitus	2.53e-05	0.000468	CcSEcCtD
Cabergoline—Decreased appetite—Metformin—type 2 diabetes mellitus	2.52e-05	0.000466	CcSEcCtD
Cabergoline—Abdominal pain—Valsartan—type 2 diabetes mellitus	2.51e-05	0.000465	CcSEcCtD
Cabergoline—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	2.51e-05	0.000464	CcSEcCtD
Cabergoline—Nausea—Bromocriptine—type 2 diabetes mellitus	2.5e-05	0.000463	CcSEcCtD
Cabergoline—Fatigue—Metformin—type 2 diabetes mellitus	2.5e-05	0.000462	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	2.49e-05	0.000461	CcSEcCtD
Cabergoline—Hyperhidrosis—Losartan—type 2 diabetes mellitus	2.49e-05	0.00046	CcSEcCtD
Cabergoline—Abdominal pain—Orlistat—type 2 diabetes mellitus	2.48e-05	0.00046	CcSEcCtD
Cabergoline—Asthenia—Gliclazide—type 2 diabetes mellitus	2.48e-05	0.00046	CcSEcCtD
Cabergoline—Constipation—Metformin—type 2 diabetes mellitus	2.48e-05	0.000458	CcSEcCtD
Cabergoline—Paraesthesia—Irbesartan—type 2 diabetes mellitus	2.45e-05	0.000454	CcSEcCtD
Cabergoline—Anorexia—Losartan—type 2 diabetes mellitus	2.45e-05	0.000454	CcSEcCtD
Cabergoline—Vomiting—Glyburide—type 2 diabetes mellitus	2.45e-05	0.000453	CcSEcCtD
Cabergoline—Pruritus—Gliclazide—type 2 diabetes mellitus	2.45e-05	0.000453	CcSEcCtD
Cabergoline—Malaise—Ramipril—type 2 diabetes mellitus	2.44e-05	0.000451	CcSEcCtD
Cabergoline—Dyspnoea—Irbesartan—type 2 diabetes mellitus	2.44e-05	0.000451	CcSEcCtD
Cabergoline—Rash—Glyburide—type 2 diabetes mellitus	2.43e-05	0.00045	CcSEcCtD
Cabergoline—Somnolence—Irbesartan—type 2 diabetes mellitus	2.43e-05	0.00045	CcSEcCtD
Cabergoline—Dermatitis—Glyburide—type 2 diabetes mellitus	2.43e-05	0.000449	CcSEcCtD
Cabergoline—Vertigo—Ramipril—type 2 diabetes mellitus	2.43e-05	0.000449	CcSEcCtD
Cabergoline—Syncope—Ramipril—type 2 diabetes mellitus	2.42e-05	0.000448	CcSEcCtD
Cabergoline—Headache—Glyburide—type 2 diabetes mellitus	2.41e-05	0.000447	CcSEcCtD
Cabergoline—Dyspepsia—Irbesartan—type 2 diabetes mellitus	2.41e-05	0.000445	CcSEcCtD
Cabergoline—Hypotension—Losartan—type 2 diabetes mellitus	2.4e-05	0.000445	CcSEcCtD
Cabergoline—Palpitations—Ramipril—type 2 diabetes mellitus	2.39e-05	0.000442	CcSEcCtD
Cabergoline—Feeling abnormal—Metformin—type 2 diabetes mellitus	2.39e-05	0.000442	CcSEcCtD
Cabergoline—Decreased appetite—Irbesartan—type 2 diabetes mellitus	2.38e-05	0.00044	CcSEcCtD
Cabergoline—Loss of consciousness—Ramipril—type 2 diabetes mellitus	2.37e-05	0.000439	CcSEcCtD
Cabergoline—Diarrhoea—Gliclazide—type 2 diabetes mellitus	2.37e-05	0.000438	CcSEcCtD
Cabergoline—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	2.37e-05	0.000438	CcSEcCtD
Cabergoline—Fatigue—Irbesartan—type 2 diabetes mellitus	2.36e-05	0.000436	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	2.34e-05	0.000434	CcSEcCtD
Cabergoline—Hypersensitivity—Valsartan—type 2 diabetes mellitus	2.34e-05	0.000434	CcSEcCtD
Cabergoline—Pain—Irbesartan—type 2 diabetes mellitus	2.34e-05	0.000432	CcSEcCtD
Cabergoline—Constipation—Irbesartan—type 2 diabetes mellitus	2.34e-05	0.000432	CcSEcCtD
Cabergoline—Insomnia—Losartan—type 2 diabetes mellitus	2.33e-05	0.00043	CcSEcCtD
Cabergoline—Hypersensitivity—Orlistat—type 2 diabetes mellitus	2.32e-05	0.000428	CcSEcCtD
Cabergoline—Paraesthesia—Losartan—type 2 diabetes mellitus	2.31e-05	0.000427	CcSEcCtD
Cabergoline—Arthralgia—Ramipril—type 2 diabetes mellitus	2.3e-05	0.000426	CcSEcCtD
Cabergoline—Dyspnoea—Losartan—type 2 diabetes mellitus	2.29e-05	0.000424	CcSEcCtD
Cabergoline—Anxiety—Ramipril—type 2 diabetes mellitus	2.29e-05	0.000424	CcSEcCtD
Cabergoline—Nausea—Glyburide—type 2 diabetes mellitus	2.29e-05	0.000424	CcSEcCtD
Cabergoline—Abdominal pain—Metformin—type 2 diabetes mellitus	2.29e-05	0.000424	CcSEcCtD
Cabergoline—Dizziness—Gliclazide—type 2 diabetes mellitus	2.29e-05	0.000424	CcSEcCtD
Cabergoline—Somnolence—Losartan—type 2 diabetes mellitus	2.29e-05	0.000423	CcSEcCtD
Cabergoline—Asthenia—Valsartan—type 2 diabetes mellitus	2.28e-05	0.000422	CcSEcCtD
Cabergoline—Discomfort—Ramipril—type 2 diabetes mellitus	2.27e-05	0.000421	CcSEcCtD
Cabergoline—Dyspepsia—Losartan—type 2 diabetes mellitus	2.26e-05	0.000419	CcSEcCtD
Cabergoline—Asthenia—Orlistat—type 2 diabetes mellitus	2.25e-05	0.000417	CcSEcCtD
Cabergoline—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	2.25e-05	0.000417	CcSEcCtD
Cabergoline—Pruritus—Valsartan—type 2 diabetes mellitus	2.25e-05	0.000416	CcSEcCtD
Cabergoline—Dry mouth—Ramipril—type 2 diabetes mellitus	2.25e-05	0.000416	CcSEcCtD
Cabergoline—Decreased appetite—Losartan—type 2 diabetes mellitus	2.24e-05	0.000414	CcSEcCtD
Cabergoline—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	2.23e-05	0.000414	CcSEcCtD
Cabergoline—Confusional state—Ramipril—type 2 diabetes mellitus	2.22e-05	0.000411	CcSEcCtD
Cabergoline—Pruritus—Orlistat—type 2 diabetes mellitus	2.22e-05	0.000411	CcSEcCtD
Cabergoline—Fatigue—Losartan—type 2 diabetes mellitus	2.22e-05	0.00041	CcSEcCtD
Cabergoline—Oedema—Ramipril—type 2 diabetes mellitus	2.21e-05	0.000408	CcSEcCtD
Cabergoline—Vomiting—Gliclazide—type 2 diabetes mellitus	2.2e-05	0.000407	CcSEcCtD
Cabergoline—Pain—Losartan—type 2 diabetes mellitus	2.2e-05	0.000407	CcSEcCtD
Cabergoline—Constipation—Losartan—type 2 diabetes mellitus	2.2e-05	0.000407	CcSEcCtD
Cabergoline—Rash—Gliclazide—type 2 diabetes mellitus	2.18e-05	0.000404	CcSEcCtD
Cabergoline—Dermatitis—Gliclazide—type 2 diabetes mellitus	2.18e-05	0.000403	CcSEcCtD
Cabergoline—Diarrhoea—Valsartan—type 2 diabetes mellitus	2.18e-05	0.000403	CcSEcCtD
Cabergoline—Shock—Ramipril—type 2 diabetes mellitus	2.17e-05	0.000401	CcSEcCtD
Cabergoline—Headache—Gliclazide—type 2 diabetes mellitus	2.17e-05	0.000401	CcSEcCtD
Cabergoline—Abdominal pain—Irbesartan—type 2 diabetes mellitus	2.16e-05	0.0004	CcSEcCtD
Cabergoline—Diarrhoea—Orlistat—type 2 diabetes mellitus	2.15e-05	0.000398	CcSEcCtD
Cabergoline—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	2.13e-05	0.000394	CcSEcCtD
Cabergoline—Feeling abnormal—Losartan—type 2 diabetes mellitus	2.12e-05	0.000392	CcSEcCtD
Cabergoline—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	2.1e-05	0.000389	CcSEcCtD
Cabergoline—Dizziness—Valsartan—type 2 diabetes mellitus	2.1e-05	0.000389	CcSEcCtD
Cabergoline—Anorexia—Ramipril—type 2 diabetes mellitus	2.1e-05	0.000389	CcSEcCtD
Cabergoline—Dizziness—Orlistat—type 2 diabetes mellitus	2.08e-05	0.000384	CcSEcCtD
Cabergoline—Asthenia—Metformin—type 2 diabetes mellitus	2.08e-05	0.000384	CcSEcCtD
Cabergoline—Hypotension—Ramipril—type 2 diabetes mellitus	2.06e-05	0.000381	CcSEcCtD
Cabergoline—Nausea—Gliclazide—type 2 diabetes mellitus	2.06e-05	0.00038	CcSEcCtD
Cabergoline—Pruritus—Metformin—type 2 diabetes mellitus	2.05e-05	0.000379	CcSEcCtD
Cabergoline—Abdominal pain—Losartan—type 2 diabetes mellitus	2.03e-05	0.000376	CcSEcCtD
Cabergoline—Vomiting—Valsartan—type 2 diabetes mellitus	2.02e-05	0.000374	CcSEcCtD
Cabergoline—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	2.01e-05	0.000373	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	2.01e-05	0.000372	CcSEcCtD
Cabergoline—Rash—Valsartan—type 2 diabetes mellitus	2.01e-05	0.000371	CcSEcCtD
Cabergoline—Dermatitis—Valsartan—type 2 diabetes mellitus	2e-05	0.000371	CcSEcCtD
Cabergoline—Vomiting—Orlistat—type 2 diabetes mellitus	2e-05	0.00037	CcSEcCtD
Cabergoline—Insomnia—Ramipril—type 2 diabetes mellitus	1.99e-05	0.000369	CcSEcCtD
Cabergoline—Headache—Valsartan—type 2 diabetes mellitus	1.99e-05	0.000369	CcSEcCtD
Cabergoline—Diarrhoea—Metformin—type 2 diabetes mellitus	1.98e-05	0.000367	CcSEcCtD
Cabergoline—Rash—Orlistat—type 2 diabetes mellitus	1.98e-05	0.000367	CcSEcCtD
Cabergoline—Paraesthesia—Ramipril—type 2 diabetes mellitus	1.98e-05	0.000366	CcSEcCtD
Cabergoline—Dermatitis—Orlistat—type 2 diabetes mellitus	1.98e-05	0.000366	CcSEcCtD
Cabergoline—Headache—Orlistat—type 2 diabetes mellitus	1.97e-05	0.000364	CcSEcCtD
Cabergoline—Dyspnoea—Ramipril—type 2 diabetes mellitus	1.97e-05	0.000364	CcSEcCtD
Cabergoline—Asthenia—Irbesartan—type 2 diabetes mellitus	1.96e-05	0.000363	CcSEcCtD
Cabergoline—Somnolence—Ramipril—type 2 diabetes mellitus	1.96e-05	0.000363	CcSEcCtD
Cabergoline—Dyspepsia—Ramipril—type 2 diabetes mellitus	1.94e-05	0.000359	CcSEcCtD
Cabergoline—Pruritus—Irbesartan—type 2 diabetes mellitus	1.93e-05	0.000358	CcSEcCtD
Cabergoline—Decreased appetite—Ramipril—type 2 diabetes mellitus	1.92e-05	0.000355	CcSEcCtD
Cabergoline—Dizziness—Metformin—type 2 diabetes mellitus	1.91e-05	0.000354	CcSEcCtD
Cabergoline—Fatigue—Ramipril—type 2 diabetes mellitus	1.9e-05	0.000352	CcSEcCtD
Cabergoline—Hypersensitivity—Losartan—type 2 diabetes mellitus	1.89e-05	0.000351	CcSEcCtD
Cabergoline—Nausea—Valsartan—type 2 diabetes mellitus	1.89e-05	0.00035	CcSEcCtD
Cabergoline—Constipation—Ramipril—type 2 diabetes mellitus	1.89e-05	0.000349	CcSEcCtD
Cabergoline—Diarrhoea—Irbesartan—type 2 diabetes mellitus	1.87e-05	0.000346	CcSEcCtD
Cabergoline—Nausea—Orlistat—type 2 diabetes mellitus	1.87e-05	0.000345	CcSEcCtD
Cabergoline—Asthenia—Losartan—type 2 diabetes mellitus	1.85e-05	0.000341	CcSEcCtD
Cabergoline—Vomiting—Metformin—type 2 diabetes mellitus	1.84e-05	0.000341	CcSEcCtD
Cabergoline—Rash—Metformin—type 2 diabetes mellitus	1.83e-05	0.000338	CcSEcCtD
Cabergoline—Dermatitis—Metformin—type 2 diabetes mellitus	1.82e-05	0.000338	CcSEcCtD
Cabergoline—Pruritus—Losartan—type 2 diabetes mellitus	1.82e-05	0.000337	CcSEcCtD
Cabergoline—Feeling abnormal—Ramipril—type 2 diabetes mellitus	1.82e-05	0.000336	CcSEcCtD
Cabergoline—Headache—Metformin—type 2 diabetes mellitus	1.81e-05	0.000336	CcSEcCtD
Cabergoline—Dizziness—Irbesartan—type 2 diabetes mellitus	1.81e-05	0.000334	CcSEcCtD
Cabergoline—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	1.8e-05	0.000334	CcSEcCtD
Cabergoline—Diarrhoea—Losartan—type 2 diabetes mellitus	1.76e-05	0.000326	CcSEcCtD
Cabergoline—Abdominal pain—Ramipril—type 2 diabetes mellitus	1.74e-05	0.000323	CcSEcCtD
Cabergoline—Vomiting—Irbesartan—type 2 diabetes mellitus	1.74e-05	0.000322	CcSEcCtD
Cabergoline—Rash—Irbesartan—type 2 diabetes mellitus	1.72e-05	0.000319	CcSEcCtD
Cabergoline—Dermatitis—Irbesartan—type 2 diabetes mellitus	1.72e-05	0.000319	CcSEcCtD
Cabergoline—Nausea—Metformin—type 2 diabetes mellitus	1.72e-05	0.000318	CcSEcCtD
Cabergoline—Headache—Irbesartan—type 2 diabetes mellitus	1.71e-05	0.000317	CcSEcCtD
Cabergoline—Dizziness—Losartan—type 2 diabetes mellitus	1.7e-05	0.000315	CcSEcCtD
Cabergoline—Vomiting—Losartan—type 2 diabetes mellitus	1.64e-05	0.000303	CcSEcCtD
Cabergoline—Hypersensitivity—Ramipril—type 2 diabetes mellitus	1.62e-05	0.000301	CcSEcCtD
Cabergoline—Nausea—Irbesartan—type 2 diabetes mellitus	1.62e-05	0.0003	CcSEcCtD
Cabergoline—Rash—Losartan—type 2 diabetes mellitus	1.62e-05	0.0003	CcSEcCtD
Cabergoline—Dermatitis—Losartan—type 2 diabetes mellitus	1.62e-05	0.0003	CcSEcCtD
Cabergoline—Headache—Losartan—type 2 diabetes mellitus	1.61e-05	0.000298	CcSEcCtD
Cabergoline—Asthenia—Ramipril—type 2 diabetes mellitus	1.58e-05	0.000293	CcSEcCtD
Cabergoline—Pruritus—Ramipril—type 2 diabetes mellitus	1.56e-05	0.000289	CcSEcCtD
Cabergoline—Nausea—Losartan—type 2 diabetes mellitus	1.53e-05	0.000283	CcSEcCtD
Cabergoline—Diarrhoea—Ramipril—type 2 diabetes mellitus	1.51e-05	0.000279	CcSEcCtD
Cabergoline—Dizziness—Ramipril—type 2 diabetes mellitus	1.46e-05	0.00027	CcSEcCtD
Cabergoline—Vomiting—Ramipril—type 2 diabetes mellitus	1.4e-05	0.000259	CcSEcCtD
Cabergoline—Rash—Ramipril—type 2 diabetes mellitus	1.39e-05	0.000257	CcSEcCtD
Cabergoline—Dermatitis—Ramipril—type 2 diabetes mellitus	1.39e-05	0.000257	CcSEcCtD
Cabergoline—Headache—Ramipril—type 2 diabetes mellitus	1.38e-05	0.000256	CcSEcCtD
Cabergoline—Nausea—Ramipril—type 2 diabetes mellitus	1.31e-05	0.000242	CcSEcCtD
Cabergoline—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	5.78e-07	1.65e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	5.78e-07	1.65e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	5.78e-07	1.65e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	5.78e-07	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.77e-07	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.76e-07	1.64e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.76e-07	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.75e-07	1.64e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.74e-07	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.73e-07	1.63e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.7e-07	1.62e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.68e-07	1.62e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.68e-07	1.62e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	5.68e-07	1.62e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.67e-07	1.62e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—SRC—type 2 diabetes mellitus	5.63e-07	1.6e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.63e-07	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	5.62e-07	1.6e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.62e-07	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.62e-07	1.6e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.58e-07	1.59e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.58e-07	1.59e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	5.53e-07	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	5.53e-07	1.58e-05	CbGpPWpGaD
Cabergoline—ADRB1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.53e-07	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.51e-07	1.57e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.51e-07	1.57e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.51e-07	1.57e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.51e-07	1.57e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.48e-07	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.48e-07	1.56e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.48e-07	1.56e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.47e-07	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.47e-07	1.56e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.44e-07	1.55e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.44e-07	1.55e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.43e-07	1.55e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.42e-07	1.54e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.42e-07	1.54e-05	CbGpPWpGaD
Cabergoline—ADRB2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.41e-07	1.54e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.4e-07	1.54e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.39e-07	1.54e-05	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—IL6—type 2 diabetes mellitus	5.38e-07	1.53e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.36e-07	1.53e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.36e-07	1.53e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.36e-07	1.53e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.35e-07	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.35e-07	1.52e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.33e-07	1.52e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.33e-07	1.52e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.32e-07	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.32e-07	1.52e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	5.31e-07	1.51e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	5.3e-07	1.51e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.29e-07	1.51e-05	CbGpPWpGaD
Cabergoline—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.29e-07	1.51e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.27e-07	1.5e-05	CbGpPWpGaD
Cabergoline—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.26e-07	1.5e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.25e-07	1.5e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.24e-07	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—SRC—type 2 diabetes mellitus	5.24e-07	1.49e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—SRC—type 2 diabetes mellitus	5.24e-07	1.49e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	5.23e-07	1.49e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	5.23e-07	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.22e-07	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.22e-07	1.49e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.21e-07	1.49e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.2e-07	1.48e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.18e-07	1.48e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.18e-07	1.48e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.17e-07	1.47e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.17e-07	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.13e-07	1.46e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.12e-07	1.46e-05	CbGpPWpGaD
Cabergoline—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.12e-07	1.46e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.1e-07	1.45e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.1e-07	1.45e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	5.1e-07	1.45e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.08e-07	1.45e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.07e-07	1.45e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.07e-07	1.44e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.06e-07	1.44e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.04e-07	1.44e-05	CbGpPWpGaD
Cabergoline—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.04e-07	1.44e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.03e-07	1.43e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.02e-07	1.43e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.02e-07	1.43e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	5.01e-07	1.43e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	5.01e-07	1.43e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.01e-07	1.43e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.99e-07	1.42e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.97e-07	1.42e-05	CbGpPWpGaD
Cabergoline—DRD5—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.96e-07	1.41e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.96e-07	1.41e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.95e-07	1.41e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.93e-07	1.41e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.93e-07	1.4e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.91e-07	1.4e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.91e-07	1.4e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.9e-07	1.4e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.87e-07	1.39e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.85e-07	1.38e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.85e-07	1.38e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.8e-07	1.37e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.79e-07	1.37e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.78e-07	1.36e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—SRC—type 2 diabetes mellitus	4.77e-07	1.36e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.74e-07	1.35e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.74e-07	1.35e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.73e-07	1.35e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.71e-07	1.34e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.68e-07	1.33e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.68e-07	1.33e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—SRC—type 2 diabetes mellitus	4.67e-07	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.66e-07	1.33e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.65e-07	1.33e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.65e-07	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.65e-07	1.32e-05	CbGpPWpGaD
Cabergoline—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.64e-07	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.61e-07	1.31e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.6e-07	1.31e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.59e-07	1.31e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.59e-07	1.31e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.57e-07	1.3e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.57e-07	1.3e-05	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.57e-07	1.3e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.56e-07	1.3e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.56e-07	1.3e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.55e-07	1.3e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	4.54e-07	1.29e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.53e-07	1.29e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.5e-07	1.28e-05	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.47e-07	1.27e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.45e-07	1.27e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.43e-07	1.26e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.42e-07	1.26e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	4.42e-07	1.26e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.4e-07	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.35e-07	1.24e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.35e-07	1.24e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.32e-07	1.23e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.32e-07	1.23e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.3e-07	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.3e-07	1.23e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.3e-07	1.23e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.28e-07	1.22e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.27e-07	1.22e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.24e-07	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.23e-07	1.21e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.23e-07	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.23e-07	1.2e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.22e-07	1.2e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.19e-07	1.19e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.18e-07	1.19e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.17e-07	1.19e-05	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.16e-07	1.18e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—type 2 diabetes mellitus	4.15e-07	1.18e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.15e-07	1.18e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.14e-07	1.18e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.14e-07	1.18e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	4.12e-07	1.17e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	4.12e-07	1.17e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.12e-07	1.17e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.09e-07	1.17e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.09e-07	1.17e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.08e-07	1.16e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.06e-07	1.16e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.06e-07	1.16e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	4.04e-07	1.15e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.01e-07	1.14e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	4.01e-07	1.14e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	4e-07	1.14e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.98e-07	1.13e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—type 2 diabetes mellitus	3.97e-07	1.13e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.95e-07	1.13e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.94e-07	1.12e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.93e-07	1.12e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.9e-07	1.11e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.89e-07	1.11e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.89e-07	1.11e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.87e-07	1.1e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.86e-07	1.1e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.85e-07	1.1e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.85e-07	1.1e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.84e-07	1.09e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.84e-07	1.09e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.83e-07	1.09e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.81e-07	1.09e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.8e-07	1.08e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.79e-07	1.08e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.77e-07	1.08e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.76e-07	1.07e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.74e-07	1.07e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.72e-07	1.06e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.69e-07	1.05e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.66e-07	1.04e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.59e-07	1.02e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.58e-07	1.02e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	3.58e-07	1.02e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.54e-07	1.01e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—type 2 diabetes mellitus	3.53e-07	1.01e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—type 2 diabetes mellitus	3.53e-07	1.01e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.52e-07	1e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.51e-07	1e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.5e-07	9.97e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.49e-07	9.96e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.48e-07	9.91e-06	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.46e-07	9.85e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.45e-07	9.84e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.38e-07	9.65e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.37e-07	9.59e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.31e-07	9.43e-06	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.3e-07	9.4e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.3e-07	9.4e-06	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	3.28e-07	9.36e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.26e-07	9.29e-06	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.25e-07	9.28e-06	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.25e-07	9.28e-06	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—type 2 diabetes mellitus	3.21e-07	9.16e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.21e-07	9.14e-06	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.19e-07	9.08e-06	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—type 2 diabetes mellitus	3.14e-07	8.96e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.14e-07	8.96e-06	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	3.07e-07	8.76e-06	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	3.06e-07	8.72e-06	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	2.98e-07	8.48e-06	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.97e-07	8.45e-06	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.94e-07	8.37e-06	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	2.93e-07	8.35e-06	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.9e-07	8.27e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.87e-07	8.19e-06	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.84e-07	8.08e-06	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.82e-07	8.04e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.82e-07	8.03e-06	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.74e-07	7.82e-06	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.7e-07	7.7e-06	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.7e-07	7.69e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	2.67e-07	7.6e-06	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.66e-07	7.57e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.6e-07	7.41e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.58e-07	7.36e-06	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.49e-07	7.1e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.47e-07	7.04e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.47e-07	7.04e-06	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.45e-07	6.98e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.42e-07	6.89e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.4e-07	6.84e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.26e-07	6.44e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.23e-07	6.35e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.14e-07	3.24e-06	CbGpPWpGaD
